ZDA
VOR icon

Zweig-DiMenna Associates’s Vor Biopharma VOR Stock Holding History

Zweig-DiMenna Associates’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$862K – 231
2021
Q1 		$862K Buy
+1,000
New +$846K 0.06% 158

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Zweig-DiMenna Associates's VOR Position: Q2 2021 in Review

Zweig-DiMenna Associates sold out of Vor Biopharma (VOR) in Q2 2021, closing a stake of 1,000 shares — an estimated $862K sold.

Zweig-DiMenna Associates first reported a position in VOR in Q1 2021 and held it in 1 quarter. The position peaked at $862K in Q1 2021. 51 funds tracked by Wall St. Rank hold VOR as of Q2 2021.

  • Zweig-DiMenna Associates reported no remaining Vor Biopharma position as of Q2 2021 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 1,000 Vor Biopharma shares in Q2 2021, an estimated $862K.
  • Zweig-DiMenna Associates first reported a position in Vor Biopharma in Q1 2021 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Vor Biopharma position peaked at $862K in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2021.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2021, filed 29 Jul 2021.